Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

[1]  M. Gulliford,et al.  Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study , 2004, Diabetes/metabolism research and reviews.

[2]  E. Cerasi,et al.  Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? , 1996, Diabetologia.

[3]  J. Leahy,et al.  Is metformin cardioprotective? , 2003, Diabetes care.

[4]  S. Majumdar,et al.  Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. , 2002, Diabetes care.

[5]  A. Tenenbaum,et al.  Oral antidiabetic treatment in patients with coronary disease: Time‐related increased mortality on combined glyburide/metformin therapy over a 7.7‐year follow‐up , 2001, Clinical cardiology.

[6]  G. Lindberg,et al.  Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study , 2000, Diabetologia.

[7]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[8]  David M Nathan,et al.  Some answers, more controversy, from UKPDS , 1998, The Lancet.

[9]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[10]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[11]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[12]  D. Boyle,et al.  The diabetes audit and research in Tayside Scotland (darts) study: electronic record linkage to create a diabetes register , 1997, BMJ.

[13]  J. Evans,et al.  The Tayside Medicines Monitoring Unit (MEMO) : a record-linkage system for pharmacovigilance , 1995 .

[14]  V. Carstairs,et al.  Deprivation and health in Scotland. , 1990, Health bulletin.

[15]  Brämer Gr.  International statistical classification of diseases and related health problems. Tenth revision. , 1988, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[16]  H. Seltzer.  A Summary of Criticisms of the Findings and Conclusions of the University Group Diabetes Program (UGDP) , 1972, Diabetes.

[17]  B. Schneider.  MANUAL of the international statistical classification of diseases, injuries, and causes of death. Addendum 1. Supplementary interpretations and instructions for coding causes of death. , 1953, Bulletin of the World Health Organization. Supplement.